Novo-owned company faces generic competition
![Foto: Orexo AB/ PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5697191.ece/ALTERNATES/schema-16_9/GMP_high.jpg)
The Sweden-based biotech company Orexo might be on the verge of losing one of its revenue streams. The company, which has a Danish CEO and is partly owned by Novo Ventures, has received notice from the US/Irish generics giant Actavis that it has submitted an Abbreviated New Drug Application (ANDA) with the FDA for a generic version of Orexo’s drug Abstral.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto CFO switches to Novo-owned company
For abonnenter
Novo Seeds in biggest ever licensing deal
For abonnenter